1-4 of 4
Juliana M. L. Biondo
Close
Sort by
Journal Articles

Patient Preferences for Fixed Versus Treat-to-Progression Therapies in Chronic Lymphocytic Leukemia

Arliene Ravelo, Kelley Myers, Claire Ervin, Robyn Brumble, Cooper Bussberg, Brian Koffman, Beenish S Manzoor, Juliana M. L. Biondo, Carol Mansfield
Journal: Blood
Blood (2023) 142 (Supplement 1): 3706.
https://doi.org/10.1182/blood-2023-174719
Published: 2023
Journal Articles

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, John M. Burke, Bertrand Anz, Shachar Peles, Jeff P. Sharman, Praveen K. Tumula, Juliana M. L. Biondo, Prachi Jani, Mei Wu, Tony Lin, Neha Parmar, Yong Mun, Nai-Shun Yao, Steven Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3029.
https://doi.org/10.1182/blood-2023-177917
Published: 2023
Journal Articles

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Hsu-Chih Chien, PhD MSc, Vikas Patil, MS, Kelli M Rasmussen, MS, Christina Yong, MA, Juliana M L Biondo, MD, Mary Halloran, PharmD, BCPS, Sheila Shapouri, PharmD, MS, Mei Wu, PharmD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4309.
https://doi.org/10.1182/blood-2019-128645
Published: 2019
Journal Articles

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Jennifer R. Brown, MD PhD, Matthew S. Davids, MD, Julie E Chang, MD, Shuo Ma, MD PhD, Juliana M L Biondo, MD, Yong Mun, PhD, Madlaina Breuleux, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4320.
https://doi.org/10.1182/blood-2019-123665
Published: 2019